Ventyx Biosciences reports successful Phase 1 trials for NLRP3 inhibitors VTX3232 and VTX2735, planning Phase 2a trials for VTX3232 in Parkinson'
Ventyx Biosciences, a clinical-stage biopharmaceutical company, provided clinical and pipeline updates during its virtual investor event. The company's NLRP3 inhibitor portfolio saw promising results, including well-tolerated Phase 1 trials for VTX3232 and VTX2735. Ventyx is planning to initiate Phase 2a trials for VTX3232 in Parkinson's disease and obesity in H2 2024, and to evaluate VTX2735 in cardiovascular diseases. The company also expects its current cash, cash equivalents, and marketable securities to fund planned operations into at least H2 2026.
March 11, 2024
4 Articles